A modified p53 overcomes mdm2-mediated oncogenic transformation: A potential cancer therapeutic agent

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5895-5901

  Lin, Jiayuh ^a   Jin, Xiaohong ^a   Page, Carmen ^a   Sondak, Vernon K ^a   Jiang, Guihua ^a   Reynolds, R Kevin ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CHORIOCARCINOMA; FIBROSARCOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; LUNG ADENOCARCINOMA; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; AMINO ACID SUBSTITUTION; ANIMALS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DNA; FIBROBLASTS; GENE AMPLIFICATION; GROWTH INHIBITORS; HUMANS; NUCLEAR PROTEINS; ONCOGENES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034667502     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Amplification of a gene encoding a p53-associated protein in human sarcomas
2. The human MDM-2 oncogene is overexpressed in leukemias
3. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas
4. MDM2 gene amplification in metastatic osteosarcoma
5. The MDM2 gene amplification database
6. Coamplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
7. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
8. Overexpression of mdm2 in mice reveals a p53-independent role for mdm2 in tumorigenesis
9. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
10. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth
11. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
12. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene
13. 1 arrest and apoptosis functions of the p53 tumor suppressor protein
14. Cell type-specific inhibition of p53-mediated apoptosis by mdm2
15. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression
16. The p53-mdm-2 autoregulatory feedback loop
17. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53
18. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
19. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
20. DNA damage induces phosphorylation of the amino terminus of p53
21. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
22. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
23. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
24. Enhanced phosphorylation of p53 by ATM in response to DNA damage
25. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
26. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization
27. mdm2 Promotes the rapid degradation of p53
28. Regulation of p53 stability by mdm2
29. Regulation of mdm2-directed degradation by the C terminus of p53
30. mdm2 Association with p53 targets its ubiquitination
31. Mapping of the p53 and mdm-2 interaction domains
32. Oncoprotein mdm2 is a ubiquitin ligase E3 for tumor suppressor p53
33. p300/MDM2 complexes participate in MDM2-mediated p53 degradation
34. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function
35. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
36. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
37. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs
38. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for mdm2-mediated degradation of p53
39. p19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
40. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
41. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
42. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
43. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
44. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export
45. p53-independent role of MDM2 in TGF-β1 resistance
46. p53 Mutation and MDM2 amplification in human soft tissue sarcomas
47. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene
48. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
49. Safety evaluation of Ad5CMV-p53 in vitro and in vivo
50. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
51. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression
52. Several hydrophobic amino acids in the p53 N-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55 kD protein
53. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
54. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
55. Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death
56. WAF1, a potential mediator of p53 tumor suppression
57. 1 arrest
58. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
59. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
60. Cooperative DNA binding of p53 with TFIID (TBP): A possible mechanism for transcriptional activation
61. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription
62. p53 Transcriptional activation mediated by coactivators TAFII40 and TAFII60
63. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
64. p53 Is required for radiation-induced apoptosis in mouse thymocytes
65. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
66. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
67. Overexpression of the MDM2 oncogene in leukemia and lymphoma
68. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
69. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer
70. c-myc Amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer
71. Myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens
72. Over-expression of the c-myc proto-oncogene in colorectal carcinoma
73. Association of amplified oncogene c-myc with an abnormally banded chromosome 8 in a human leukemia cell line
74. Role for cyclin D1 in UVC-induced and p53-mediated apoptosis
75. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1
76. Analysis of wild-type and mutant p21(WAF-1) gene activities
77. Mediation of c-Myc-induced apoptosis by p53
78. A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
79. Adenovirus-mediated p53 gene transfer in advanced nonsmall-cell lung cancer